Back to top

Image: Bigstock

Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session

Read MoreHide Full Article

Puma Biotechnology, Inc. (PBYI - Free Report) was a big mover last session, as its shares rose over 30% on the day. The move came after the Food and Drug Administration (FDA) advisory committee voted 12-4 recommending that Puma's breast-cancer drug neratinib be approved. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 95% in the past one-month time frame.

The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Puma Biotechnology currently carriess a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.

Another top ranked stock from the Medical - Biomedical and Genetics space is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
    
Is PBYI going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Puma Biotechnology, Inc. (PBYI) - free report >>

Published in